Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Lexicon Pharmaceuticals is selling rights to its only marketed drug outside of the U.S. and Europe amid a ...

PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Lexicon Pharmaceuticals LXRX in the last three months. The following table summarizes their ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), retaining the price target of $10.00. Joseph Pantginis has given his Buy ...

Do you know what a morpheme is? And did you know that it's not only an atom that has a nucleus? The Babel Lexicon of Language is an entertaining and accessible introduction to the key terminology ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a price target of $10.00. The company’s shares ...

In this Lexicon, authored by an international team of scholars, over 200 entries define and explain the key concepts, categories, philosophemes, themes, debates, and names associated with the entire ...